Serial proteomic analysis identifies small extracellular vesicle-MASP2 as an early biomarker of chemotherapy response in advanced pancreatic cancer
Complement pathway activity tracks with chemotherapy response and resistance in PC. Changes in sEV-MASP2 may serve as an early predictive/prognostic biomarker, helping to improve decision making in this lethal malignancy.
Authors
- Pramila Krumholtz
- Nader T. Okby
- Richard C. Frank (ORCID: https://orcid.org/0000-0002-5923-7171)
- Mohammadreza Shervinrad
- Bhavna Khandpur
- Sarah Evans (ORCID: https://orcid.org/0000-0002-6390-6729)
- Shatovisha Dey (ORCID: https://orcid.org/0000-0003-3837-481X)
- Kiyoe Sullivan
- Deborah August
- Deep Pandya
- Ryan Narbutas
- Saraswathi Nair
- Tammy Lo (ORCID: https://orcid.org/0000-0002-7980-9595)
- Gregory Niland
Institutions
- Norwalk Hospital (US)
- Truven Health Analytics (United States) (US)
- Národní Ústav pro Vzdělávání (CZ)
- Biomedical Research Institute (US)
- Covance (United States) (US)
Publication Details
- Journal
- Translational Oncology
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1016/j.tranon.2025.102636
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00